<img height="1" width="1" src="https://www.facebook.com/tr?id=1582471781774081&amp;ev=PageView &amp;noscript=1">
  • Menu
  • crown-logo-symbol-1-400x551

Find it Quickly

Get Started

Select the option that best describes what you are looking for

  • Services
  • Models
  • Scientific Information

Search Here For Services

Click Here to Start Over

Search Here For Models

Click Here to Start Over

Search Here For Scientific Information

Click Here to Start Over

In Vitro

Boost oncology drug discovery with XenoBase®, featuring the largest cell line selection and exclusive 3D organoid models. Benefit from OrganoidXplore™ and OmniScreen™ for rapid, in-depth analysis.

Learn More

In Vivo

Enhance drug development with our validated in vivo models, in vitro/ex vivo assays, and in silico modeling. Tailored solutions to optimize your candidates.

Learn More

Tissue

Experience ISO-certified biobanking quality. Access top biospecimens from a global clinical network, annotated by experts for precise research.

Learn More

Biomarkers and Bioanalysis

Leverage our global labs and 150+ scientists for fast, tailored project execution. Benefit from our expertise, cutting-edge tech, and validated workflows for reliable data outcomes.

Learn More

Data Science and Bioinformatics

Harness your data and discover biomarkers with our top bioinformatics expertise. Maximize data value and gain critical insights to accelerate drug discovery and elevate projects.

Learn More

KRAS

Accelerate innovative cancer treatments with our advanced models and precise drug screening for KRAS mutations, efficiently turning insights into clinical breakthroughs.

Learn More

EGFR

Advance translational pharmacology with our diverse pre-clinical models, robust assays, and data science-driven biomarker analysis, multi-omics, and spatial biology.

Learn More

Drug Resistance

Our suite integrates preclinical solutions, bioanalytical read-outs, and multi-omics to uncover drug resistance markers and expedite discovery with our unique four-step strategy.

Learn More

Patient Tissue

Enhance treatments with our human tumor and mouse models, including xenografts and organoids, for accurate cancer biology representation.

Learn More

Bioinformatics

Apply the most appropriate in silico framework to your pharmacology data or historical datasets to elevate your study design and analysis, and to improve your chances of clinical success.

Learn More

Biomarker Analysis

Integrate advanced statistics into your drug development projects to gain significant biological insight into your therapeutic candidate, with our expert team of bioinformaticians.

Learn More

CRISPR/Cas9

Accelerate your discoveries with our reliable CRISPR solutions. Our global CRISPR licenses cover an integrated drug discovery platform for in vitro and in vivo efficacy studies.

Learn More

Genomics

Rely on our experienced genomics services to deliver high quality, interpretable results using highly sensitive PCR-based, real-time PCR, and NGS technologies and advanced data analytics.

Learn More

In Vitro High Content Imaging

Gain more insights into tumor growth and disease progression by leveraging our 2D and 3D fluorescence optical imaging.

Learn More

Mass Spectrometry-based Proteomics

Next-generation ion mobility mass spectrometry (MS)-based proteomics services available globally to help meet your study needs.

Learn More

Ex Vivo Patient Tissue

Gain better insight into the phenotypic response of your therapeutic candidate in organoids and ex vivo patient tissue.

Learn More

Spatial Multi-Omics Analysis

Certified CRO services with NanoString GeoMx Digital Spatial Profiling.

Learn More

Biomarker Discovery

De-risk your drug development with early identification of candidate biomarkers and utilize our biomarker discovery services to optimize clinical trial design.

Learn More

DMPK Services

Rapidly evaluate your molecule’s pharmaceutical and safety properties with our in vivo drug metabolism and pharmacokinetic (DMPK) services to select the most robust drug formulations.

Learn More

Efficacy Testing

Explore how the novel HuGEMM™ and HuCELL™ platforms can assess the efficacy of your molecule and accelerate your immuno-oncology drug discovery programs.

Learn More

Laboratory Services

Employ cutting-edge multi-omics methods to obtain accurate and comprehensive data for optimal data-based decisions.

Learn More

Pharmacology & Bioanalytical Services

Leverage our suite of structural biology services including, recombinant protein expression and protein crystallography, and target validation services including RNAi.

Learn More

Screens

Find the most appropriate screen to accelerate your drug development: discover in vivo screens with MuScreen™ and in vitro cell line screening with OmniScreen™.

Learn More

Toxicology

Carry out safety pharmacology studies as standalone assessments or embedded within our overall toxicological profiling to assess cardiovascular, metabolic and renal/urinary systems.

Learn More

Our Company

Global CRO in California, USA offering preclinical and translational oncology platforms with high-quality in vivo, in vitro, and ex vivo models.

Learn More

Our Purpose

Learn more about the impact we make through our scientific talent, high-quality standards, and innovation.

Learn More

Our Responsibility

We build a sustainable future by supporting employee growth, fostering leadership, and exceeding customer needs. Our values focus on innovation, social responsibility, and community well-being.

Learn More

Meet Our Leadership Team

We build a sustainable future by fostering leadership, employee growth, and exceeding customer needs with innovation and social responsibility.

Learn More

Scientific Advisory Board

Our Scientific Advisory Board of experts shapes our strategy and ensures top scientific standards in research and development.

Learn More

News & Events

Stay updated with Crown Bioscience's latest news, achievements, and announcements. Check our schedule for upcoming events and plan your visit.

Learn More

Career Opportunities

Join us for a fast-paced career addressing life science needs with innovative technologies. Thrive in a respectful, growth-focused environment.

Learn More

Scientific Publications

Access our latest scientific research and peer-reviewed articles. Discover cutting-edge findings and insights driving innovation and excellence in bioscience.

Learn More

Resources

Discover valuable insights and curated materials to support your R&D efforts. Explore the latest trends, innovations, and expertly curated content in bioscience.

Learn More

Blogs

Explore our blogs for the latest insights, research breakthroughs, and industry trends. Stay educated with expert perspectives and in-depth articles driving innovation in bioscience.

Learn More

  • Platforms
  • Target Solutions
  • Technologies
  • Service Types

Genetic Abnormality Spectrum in Hematologic Cancers

hematopoeisis, graphic showing the development of different blood cells in humans including morphological characteristics

hematopoeisis, graphic showing the development of different blood cells in humans including morphological characteristicsWhat have we learned about the genetics of hematological cancers, and how can that be modelled for research and drug discovery?

How Does Hematological Cancer Develop?

Hematopoiesis is a dynamic developmental process, arising from hematopoietic stem cells (HSCs) in the bone marrow to maintain the lifelong regeneration of blood cells. Perturbation of normal hematopoietic differentiation results in hematological cancers. These are subdivided into three main types: multiple myeloma, leukemia, and lymphoma.

This post reviews the differences in genetic abnormalities across the range of hematologic malignancies, the variety of targeted agents developed, and the preclinical models used to assess potential new therapeutics.

Multiple Myeloma (MM)

Multiple myeloma affects the plasma cells within the bone marrow that are responsible for the production of antibodies. Plasma cells accumulate in the marrow, and damage or weaken the bone, inducing bone pain. Cancerous plasma cells can also produce abnormal antibodies which alter the humoral immune response, increasing the risk of infection and the ability to combat infection.

The cause of MM is not clearly identified. The most commonly reported genetic changes are in KRAS, NRAS, TP53, FAM46C, BRAF, DIS3, ATM, and CCND1. These genetic changes play a role in the pathogenesis of MM, providing prognostic and therapeutic targets for novel therapies.

Over the past decade, treatment options for multiple myeloma have increased substantially, including:

  • Chemotherapies.
  • Corticosteroids.
  • Immunomodulating agents (thalidomide, lenalidomide, pomalidomide).
  • Proteasome inhibitors (bortezomib, carfilzomib, ixazomib).
  • HDAC inhibitors (panobinostat).
  • Monoclonal antibodies (daratumumab, elotuzumab).

Leukemia

Leukemia is caused by excessive production of abnormal white blood cells in bone marrow, which then circulate in to the blood. Leukemia can be categorized into multiple subtypes: acute lymphocytic leukemia (ALL), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), and chronic myeloid leukemia (CML). Acute leukemias are fast-growing and may require aggressive treatments.

Acute Lymphocytic Leukemia (ALL)

Although the primary genetic lesions that cause the vast majority of ALL are still unknown, a high frequency of genetic abnormalities are observed. In B-ALL this includes:

  • Translocations (such as ETV6/RUNX1, BCR/ABL1, TCF3/PBX1).
  • MLL rearrangement involving 11q23 with a wide range of partner genes.
  • Rearrangement of MYC into antigen receptor gene loci.
  • Mutations of genes involved in tumorigenesis or tumor suppression, apoptosis, and cell cycle regulation (e.g. CRLF2, IKZF1, TP53, and FLT3).

In T cell ALL, LYL1, TAL1, TLX1, and TLX3 rearrangements occur.

The main treatment for ALL in adults is typically long-term combination chemotherapy. This incorporates tyrosine kinase inhibitor targeted therapy (e.g. imatinib, dasatinib, nilotinib, ponatinib, bosutinib) for patients harboring BCR-ABL rearrangement.

Immunotherapies are also used as second line treatment for refractory or relapsed ALL. This includes blinatumomab a bispecific T-cell engager targeting CD19, the monoclonal antibody inotuzumab ozogamicin against CD22, or the CAR-T cell therapy tisagenlecleucel (Kymriah®) targeting CD19. Radiation therapy can be also use in certain situations.

Acute Myeloid Leukemia (AML)

AML is a heterogeneous disease whose onset involves a variety of chromosomal abnormalities and gene mutations. The most important of these gene mutations for differentiated prognosis are the internal tandem duplication (FLT3-ITD), NPM1, IDH1, IDH2, and CEBPA gene mutations.

The main treatment for most types of AML is chemotherapy, commonly using cytarabine or anthracycline drugs. Sometimes targeted therapies are used in combination with chemotherapy, such as adding FLT3 inhibitors (midostaurin, gilteritinib) or IDH inhibitors (ivosidenib, enasidenib).

Chronic Lymphocytic Leukemia (CLL)

In CLL, TP53 is the most clinically adverse mutation, with less frequent mutations observed in NOTCH1, SF3B1, PO1, EGR2, MYD88, the WNT pathway, and deletion 11q-associated mutations (ATM, BIRC3). Mutations in BTK and PLCG2 are also found in approximately 80% of CLL patients with acquired resistance to ibrutinib.

CLL is treated by a variety of different drug types, such as:

  • Chemotherapy.
  • Radiation therapy.
  • Monoclonal antibodies targeting CD20 (rituximab, obinutuzumab, ofatumumab).
  • mAb targeting CD52 (alemtuzumab).
  • mAb targeting CD22 (Lumoxiti™).
  • BTK inhibitors (ibrutinib).
  • PI3K inhibitors (idelalisib, duvelisib).
  • Bcl-2 inhibitors (venetoclax).
  • Autologous stem cell transplantation.

Chronic Myeloid Leukemia (CLML)

The primary cause of CML is BCR-ABL gene rearrangement. Additional chromosomal changes and mutations in tumor suppressor genes and oncogenes (e.g. p53, Rb1, or Ras), are required for the progression from chronic to acute leukemia.

As CML patients harbor BCR-ABL rearrangement, targeted therapy using tyrosine kinase inhibitors (imatinib, dasatinib, nilotinib, ponatinib, bosutinib) is the standard treatment. Chemotherapy or interferon therapies are also used.

Lymphoma

Around half of the hematologic cancers that occur each year are lymphomas, or cancers of the lymphatic system. Lymphomas develop from lymphocytes (T or B cells) that expand out of control. They circulate through the blood and lymphatic system to reach and grow in many parts of the body, including the lymph nodes, spleen, bone marrow, and other organs.

There are dozens of types of lymphoma. The two main categories are Hodgkin's lymphomas (HL); and non-Hodgkin lymphomas (NHL) which account for approximately 90% of disease.

HL is marked by the presence of Reed-Sternberg cells, which are mature B cells that have become malignant. By contrast, NHL is derived from B cells or T cells, and can arise in the lymph nodes as well as other organs.

Prognoses and treatments are different for HL, and also differ between the many forms of NHL. In HL, in addition to chemotherapy or radiotherapy, immunotherapy is used, such as monoclonal antibody anti-CD30 (brentuximab vedotin), anti-CD20 (rituximab) or immune checkpoint inhibitors targeting anti-PD1 (nivolumab, pembrolizumab).

NHL has some overlap in the treatments that are used. In addition to chemotherapy or radiotherapy, immunotherapies which are approved include:

  • Monoclonal antibody anti-CD30 (brentuximab vedotin).
  • mAb anti-CD20 (rituximab, obinutuzumab, ofatumumab, ibritumomab tiuxetan).
  • mAb anti-CD52 (alemtuzumab).
  • Immune checkpoint inhibitor anti-PD1 (nivolumab, pembrolizumab).
  • Immunomodulating drugs (thalidomide, lenalidomide).
  • CD19 CAR-T therapy (axicabtagene ciloleucel, tisagenlecleucel).

Preclinical Models for Testing Hematologic Cancer Agents

Translational preclinical models are needed to help to better understand the complex biology of hematologic cancers and to evaluate potential new or combination therapies.

Models of hematologic malignancies have traditionally been cell line derived xenograft models, using cell lines which have been immortalized from patient tissues in vitro.

Highly predictive patient-derived xenograft (PDX) preclinical models have also been developed from a patient’s blood, which are implanted directly into mice without in vitro propagation. To develop these models, peripheral blood or bone marrow is taken from patients, and implanted into mice to generate the original model. This model is utilized to evaluate lead compounds for a variety of pharmacological properties (PD, efficacy, etc.), as well as disease indication and demographic specificity.

Despite the challenges in developing those models, a significant number of models are now available depending of the indication and subtype. For instance, a variety of AML phenotypes are now represented. This includes models which are not very differentiated and mostly limited to the bone marrow, and PDX which show more differentiated disease, moving into peripheral organs and with features such as enlarged spleens.

As PDX models closely reflect patient tumor histo- and molecular pathology they offer a highly predictive model for preclinical drug evaluation for hematologic cancer.

Summary

The wide variety of hematologic cancer genotypes and phenotypes means that a raft of targeted agents, immunotherapies, and combination regimens are needed to combat the disease. Preclinical models are needed which capture the clinical disease diversity, and PDX offer a predictive option when assessing the next generation of hematologic cancer agents.


Related Posts